Unione Europea - italiano - EMA (European Medicines Agency)

roche registration gmbh - atezolizumab - carcinoma, transitional cell; carcinoma, non-small-cell lung; urologic neoplasms; breast neoplasms; small cell lung carcinoma - agenti antineoplastici - urothelial carcinomatecentriq as monotherapy is indicated for the treatment of adult patients with locally advanced or metastatic urothelial carcinoma (uc):- after prior platinum containing chemotherapy, or - who are considered cisplatin ineligible, and whose tumours have a pd-l1 expression ≥ 5% (see section 5. non-small cell lung cancer tecentriq, in combination with bevacizumab, paclitaxel and carboplatin, is indicated for the first-line treatment of adult patients with metastatic non-squamous non small cell lung cancer (nsclc). in patients with egfr mutant or alk-positive nsclc, tecentriq, in combination with bevacizumab, paclitaxel and carboplatin, is indicated only after failure of appropriate targeted therapies (see section 5. tecentriq, in combination with nab paclitaxel and carboplatin, is indicated for the first line treatment of adult patients with metastatic non-squamous nsclc who do not have egfr mutant or alk positive nsclc (see section 5. tecentriq as monotherapy is indicated for the first-line treatment of adult patients with metastatic non-small cell lung cancer (nsclc) whose tumours have a pd-l1 expression ≥ 50% tumour cells (tc) or ≥ 10% tumour-infiltrating immune cells (ic) and who do not have egfr mutant or alk-positive nsclc (see section 5. tecentriq come monoterapia è indicato per il trattamento di pazienti adulti con carcinoma localmente avanzato o metastatico nsclc dopo una precedente chemioterapia. patients with egfr mutant or alk positive nsclc should also have received targeted therapies before receiving tecentriq (see section 5. small cell lung cancertecentriq, in combination with carboplatin and etoposide, is indicated for the first-line treatment of adult patients with extensive-stage small cell lung cancer (es-sclc) (see section 5. hepatocellular carcinomatecentriq, in combination with bevacizumab, is indicated for the treatment of adult patients with advanced or unresectable hepatocellular carcinoma (hcc) who have not received prior systemic therapy (see section 5. urothelial carcinomatecentriq as monotherapy is indicated for the treatment of adult patients with locally advanced or metastatic urothelial carcinoma (uc):- after prior platinum containing chemotherapy, or- who are considered cisplatin ineligible, and whose tumours have a pd-l1 expression ≥ 5% (see section 5. non-small cell lung cancertecentriq as monotherapy is indicated for the first-line treatment of adult patients with metastatic non-small cell lung cancer (nsclc) whose tumours have a pd-l1 expression ≥ 50% tumour cells (tc) or ≥ 10% tumour-infiltrating immune cells (ic) and who do not have egfr mutant or alk-positive nsclc (see section 5. tecentriq come monoterapia è indicato per il trattamento di pazienti adulti con carcinoma localmente avanzato o metastatico nsclc dopo una precedente chemioterapia. patients with egfr mutant or alk positive nsclc should also have received targeted therapies before receiving tecentriq (see section 5. triple-negative breast cancertecentriq in combination with nab-paclitaxel is indicated for the treatment of adult patients with unresectable locally advanced or metastatic triple-negative breast cancer (tnbc) whose tumours have pd-l1 expression ≥ 1% and who have not received prior chemotherapy for metastatic disease.

Unione Europea - italiano - EMA (European Medicines Agency)

chiesi farmaceutici s.p.a. - deferiprone - beta-thalassemia; iron overload - tutti gli altri prodotti terapeutici - la monoterapia con ferriprox è indicata per il trattamento del sovraccarico di ferro nei pazienti con talassemia major quando l'attuale terapia di chelazione è controindicata o inadeguata. questo farmaco in combinazione con un altro chelante è indicato nei pazienti con talassemia major, quando la monoterapia con qualsiasi agente chelante del ferro è inefficace, o quando la prevenzione o il trattamento di conseguenze pericolose per la vita del sovraccarico di ferro (soprattutto sovraccarico cardiaco) giustifica rapida o per la cpu correzione.

Svizzera - italiano - Swissmedic (Swiss Agency for Therapeutic Products)

mepha pharma ag - deferasiroxum - lactab - deferasiroxum 90 mg, crospovidonum, cellulosum microcristallinum, poloxamerum 188, povidonum k 30, magnesii stearas, silica colloidalis anhydrica, Überzug: hypromellosum, e 171, macrogolum 4000, e 132, talcum, pro compresso obducto. - transfusionsbedingte eisenüberladung - synthetika

Svizzera - italiano - Swissmedic (Swiss Agency for Therapeutic Products)

mepha pharma ag - deferasiroxum - lactab - deferasiroxum 180 mg, crospovidonum, cellulosum microcristallinum, poloxamerum 188, povidonum k 30, silica colloidalis anhydrica, magnesii stearas, Überzug: hypromellosum, e 171, macrogolum 4000, e 132, talcum, pro compresso obducto. - transfusionsbedingte eisenüberladung - synthetika

Svizzera - italiano - Swissmedic (Swiss Agency for Therapeutic Products)

mepha pharma ag - deferasiroxum - lactab - deferasiroxum 360 mg, crospovidonum, cellulosum microcristallinum, poloxamerum 188, povidonum k 30, silica colloidalis anhydrica, magnesii stearas, Überzug: hypromellosum, e 171, macrogolum 4000, e 132, talcum, pro compresso obducto. - transfusionsbedingte eisenüberladung - synthetika

Svizzera - italiano - Swissmedic (Swiss Agency for Therapeutic Products)

mepha pharma ag - deferasiroxum - lactab - deferasiroxum 900 mg, crospovidonum, cellulosum microcristallinum, poloxamerum 188, povidonum k 30, silica colloidalis anhydrica, magnesii stearas, Überzug: hypromellosum, e 171, macrogolum 4000, talcum, pro compresso obducto. - transfusionsbedingte eisenüberladung - synthetika

Svizzera - italiano - Swissmedic (Swiss Agency for Therapeutic Products)

accord healthcare ag - deferasiroxum - compresse rivestite con film - deferasiroxum 90 mg, cellulosum microcristallinum, carmellosum natricum conexum, hydroxypropylcellulosum substitutum humile, poloxamerum 188, povidonum k 30, lactosum monohydricum 27.025 mg, silica colloidalis anhydrica, natrii stearylis fumaras, ricini oleum hydrogenatum, Überzug: hypromellosum, propylenglycolum, talcum, e 171, e 172 (flavum), pro compresso obducto corresp. natrium 0.5447 mg. - transfusionsbedingte eisenüberladung - synthetika

Svizzera - italiano - Swissmedic (Swiss Agency for Therapeutic Products)

accord healthcare ag - deferasiroxum - compresse rivestite con film - deferasiroxum 180 mg, cellulosum microcristallinum, carmellosum natricum conexum, hydroxypropylcellulosum substitutum humile, poloxamerum 188, povidonum k 30, lactosum monohydricum 54.05 mg, silica colloidalis anhydrica, natrii stearylis fumaras, ricini oleum hydrogenatum, Überzug: hypromellosum, propylenglycolum, talcum, e 171, e 172 (flavum), pro compresso obducto corresp. natrium 1.0894 mg. - transfusionsbedingte eisenüberladung - synthetika

Svizzera - italiano - Swissmedic (Swiss Agency for Therapeutic Products)

accord healthcare ag - deferasiroxum - compresse rivestite con film - deferasiroxum 360 mg, cellulosum microcristallinum, carmellosum natricum conexum, hydroxypropylcellulosum substitutum humile, poloxamerum 188, povidonum k 30, lactosum monohydricum 108.1 mg, silica colloidalis anhydrica, natrii stearylis fumaras, ricini oleum hydrogenatum, Überzug: hypromellosum, propylenglycolum, talcum, e 171, e 172 (flavum), pro compresso obducto corresp. natrium 2.1788 mg. - transfusionsbedingte eisenüberladung - synthetika

Italia - italiano - Ministero della Salute

efer endoscopy -